Stay informed with our curated selection of industry articles, offering the latest insights and trends in drug development and clinical trials. Explore the latest trends, research breakthroughs, and industry updates to keep you informed.
Quantifying Site Burden to Optimize Protocol Performance Maria Florez, Zachary Smith, Zachary Olah, Mike Martin, Kenneth Getz | Published: January 8, 2024 |The Drug Information Association, Inc.
The introduction of Decentralized Clinical Trials—trials supported by remote and virtual technologies and services—is expected to impact the burden imposed on sites, but this impact has not yet been systematically measured.
Examining the Association Between DCT Solutions Use and Participant Diversity in Clinical Trials Zachary Smith, Kenneth Getz | Published: May 1, 2024 |The Drug Information Association, Inc.
Whereas anecdotal reports suggest that the use of decentralized clinical trial (DCT) solutions can improve participant diversity in clinical trials, there is no quantitative evidence to support such reports. Tufts CSDD conducted an initial study to compare and contrast participant diversity in trials, including various DCT solutions – virtual visits or televisits, home visits, devices or wearables, and local labs.
Assessing the Financial Value of Decentralized Clinical Trials Joseph A. DiMasi, Zachary Smith, Ingrid Oakley‑Girvan, Andrew Mackinnon, Mary Costello, Pamela Tenaerts, Kenneth A. Getz | Published: September 14, 2022 |The Drug Information Association, Inc.
The deployment of remote and virtual clinical trial methods and technologies, referred to collectively as decentralized clinical trials (DCTs), represents a profound shift in clinical trial practice. To our knowledge, a comprehensive assessment of the financial net benefits of DCTs has not been conducted. Tufts CSDD developed an expected net present value (eNPV) model of the cash flows for new drug development and commercialization to assess the financial impact of DCTs.